{'fraction_non_alphanumeric': 0.016771488469601678, 'fraction_numerical': 0.008385744234800839, 'mean_word_length': 5.732394366197183, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comparing results after surgery in patients with clinical unilateral T3a prostate cancer treated with or without neoadjuvant androgen‐deprivation therapy

To compare the results in patients with unilateral cT3 prostate cancer treated with or with no neoadjuvant androgen‐deprivation therapy (nADT), as nADT might have benefit in cT2 prostate cancer, but for cT3 tumours its use remains controversial, and it is unclear whether it can prevent or delay progression after surgery.